


This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (*original*) A compound of Formula I:



I

wherein

X-Y is $-N=C(R^4)-$, $-NH-C(O)-$, $-NH-C(O)-C(O)-$, $-NH-C(S)-$ or $-NH-S(O)_2-$;

Z is O, S or NR^5 , in which R^5 is hydrogen or alkyl of 1 to 6 carbon atoms;

R^1 , R^2 and R^3 are, independently, hydrogen, hydroxy, halo, cyano, carboxamido, carboalkoxy of two to six carbon atoms, trifluoromethyl, alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, alkanoyl of 2 to 6 carbon atoms, alkanoyloxy of 2 to 6 carbon atoms, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms, alkanamido of 2 to 6 carbon atoms, alkanesulfonyl of 1 to 6 carbon atoms or alkanesulfonamido of 1 to 6 carbon atoms;

R^4 is hydrogen, halo, amino, mono- or di-alkylamino in which each alkyl group has 1 to 6 carbon atoms or alkyl of 1 to 6 carbon atoms;


the dotted line represents an optional double bond; and

n is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof.

2. (*original*) A compound according to claim 1, wherein R^4 is hydrogen, amino or alkyl of 1 to 6 carbon atoms.

3. (*original*) A compound according to claim 1, wherein R^4 is hydrogen or alkyl of 1 to 3 carbon atoms.
4. (*original*) A compound according to claim 1, wherein X-Y is -NH-C(O)-.
5. (*original*) A compound according to claim 1, wherein Z is NR^5 .
6. (*original*) A compound according to claim 1, wherein the dotted line is a double bond.
7. (*original*) A compound according to claim 1, wherein n is 0.
8. (*original*) A compound according to claim 1 having Formula Ia:



Ia

or a pharmaceutically acceptable salt thereof.

9. (*original*) A compound according to claim 1, wherein R^5 is hydrogen or alkyl of 1 to 3 carbon atoms.
10. (*original*) A compound according to claim 1, wherein R^5 is hydrogen or methyl.
11. (*original*) A compound according to claim 1, wherein R^1 is hydrogen, halo, cyano, trifluoromethyl, alkyl of 1 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms.
12. (*original*) A compound according to claim 1, wherein R^1 is hydrogen, halo or alkoxy of 1 to 6 carbon atoms.

13. (*original*) A compound according to claim 1, wherein R¹ is hydrogen.
14. (*original*) A compound according to claim 1, wherein R² and R³ are independently selected from hydrogen, hydroxy, halo, cyano, carboxamido, alkyl of 1 to 6 carbon atoms or alkoxy of 1 to 6 carbon atoms.
15. (*original*) A compound according to claim 1, wherein R² and R³ are independently selected from hydrogen, hydroxy, halo, cyano, carboxamido, alkyl of 1 to 6 carbon atoms, or alkoxy of 1 to 6 carbon atoms.
16. (*original*) A compound according to claim 1, wherein R² and R³ are independently selected from hydrogen, cyano or halogen.
17. (*original*) A compound according to claim 1, wherein R¹ is hydrogen, halo or alkoxy of 1 to 6 carbon atoms, R² and R³ are hydrogen, cyano or halogen, R⁴ is hydrogen or alkyl of 1 to 3 carbon atoms, Z is NR⁵, R⁵ is hydrogen or alkyl of 1 to 3 carbon atoms and n is 0.
18. (*original*) A compound according to claim 1, wherein said compound is 4-{[4-(1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]methyl}-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one or a pharmaceutically acceptable salt thereof.
19. (*original*) A compound according to claim 1, wherein said compound is 4-{[4-(5-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl]methyl}-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one or a pharmaceutically acceptable salt thereof.

20. (*original*) A compound according to claim 1, wherein said compound is 4-{{4-(5-chloro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl}-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one or a pharmaceutically acceptable salt thereof.
21. (*original*) A compound according to claim 1, wherein said compound is 3-{1-[(2-oxo-1,2,4,5-tetrahydroimidazo[1,5,4-de][1,4]benzoxazin-4-yl)methyl]-1,2,3,6-tetrahydropyridin-4-yl}-1H-indole-5-carbonitrile or a pharmaceutically acceptable salt thereof.
22. (*original*) A compound according to claim 1, wherein said compound is 4-{{4-(7-fluoro-1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl}-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one or a pharmaceutically acceptable salt thereof.
23. (*original*) A compound according to claim 1, wherein said compound is 4-{{4-(1H-indol-3-yl)-3,6-dihydropyridin-1(2H)-yl)methyl}-2-methyl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazine or a pharmaceutically acceptable salt thereof.
24. (*original*) A compound according to claim 1, wherein said compound is the S enantiomer, substantially free of the R enantiomer of said compound.
25. (*currently amended*) A method of treating a subject suffering from a condition selected from depression, anxiety, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, attention deficit disorder, obsessive compulsive disorder, social anxiety disorder, generalized anxiety disorder, obesity, **eating disorders, anorexia nervosa, bulimia nervosa**, vasomotor flushing, cocaine and alcohol addiction, and **sexual dysfunction, premature ejaculation**, comprising the step of:
- administering to said subject suffering from said condition, a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

26. *(original)* A method according to claim 25, wherein the condition is depression.
27. *(original)* A method according to claim 25, wherein the condition is selected from the group consisting of obsessive-compulsive disorder, panic attacks, generalized anxiety disorder, and social anxiety disorder.
28. *(original)* A pharmaceutical composition, comprising:
an effective amount of compound according to claim 1 or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier or excipient.